SG10201608671SA - Engineered Microbe-Targeting Molecules and Uses Thereof - Google Patents

Engineered Microbe-Targeting Molecules and Uses Thereof

Info

Publication number
SG10201608671SA
SG10201608671SA SG10201608671SA SG10201608671SA SG10201608671SA SG 10201608671S A SG10201608671S A SG 10201608671SA SG 10201608671S A SG10201608671S A SG 10201608671SA SG 10201608671S A SG10201608671S A SG 10201608671SA SG 10201608671S A SG10201608671S A SG 10201608671SA
Authority
SG
Singapore
Prior art keywords
targeting molecules
engineered microbe
microbe
engineered
targeting
Prior art date
Application number
SG10201608671SA
Inventor
E Ingber Donald
Super Michael
Charles Way Jeffrey
j cartwright Mark
Watters Alexander
B Berthet Julia
R Super Dinah
M Rottman Martin
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of SG10201608671SA publication Critical patent/SG10201608671SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C07K14/42—Lectins, e.g. concanavalin, phytohaemagglutinin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54353—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56916—Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56938—Staphylococcus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56961—Plant cells or fungi
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/415—Assays involving biological materials from specific organisms or of a specific nature from plants
    • G01N2333/42—Lectins, e.g. concanavalin, phytohaemagglutinin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4724—Lectins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
SG10201608671SA 2011-07-18 2012-07-18 Engineered Microbe-Targeting Molecules and Uses Thereof SG10201608671SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161508957P 2011-07-18 2011-07-18
US201261605081P 2012-02-29 2012-02-29
US201261605052P 2012-02-29 2012-02-29

Publications (1)

Publication Number Publication Date
SG10201608671SA true SG10201608671SA (en) 2016-12-29

Family

ID=46642620

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201608671SA SG10201608671SA (en) 2011-07-18 2012-07-18 Engineered Microbe-Targeting Molecules and Uses Thereof

Country Status (8)

Country Link
US (4) US9593160B2 (en)
EP (2) EP3081937B1 (en)
JP (4) JP2014523914A (en)
AU (2) AU2012284097B2 (en)
CA (2) CA3149018A1 (en)
SG (1) SG10201608671SA (en)
WO (1) WO2013012924A2 (en)
ZA (2) ZA201400560B (en)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007044642A2 (en) 2005-10-06 2007-04-19 President And Fellows Of Harvard College And Children's Medical Center Corporation Device and method for combined microfluidic-micromagnetic separation of material in continuous flow
CN103203048A (en) 2005-12-13 2013-07-17 埃克塞拉医学有限责任公司 Method For Extracorporeal Removal Of A Pathogenic Microbe, An Inflammatory Cell Or An Inflammatory Protein From Blood
ATE534415T1 (en) 2005-12-13 2011-12-15 Harvard College SCAFFOLDS FOR CELL TRANSPLANTATION
US9156037B2 (en) 2009-01-15 2015-10-13 Children's Medical Center Corporation Microfluidic device and uses thereof
US8741591B2 (en) 2009-10-09 2014-06-03 The Research Foundation For The State University Of New York pH-insensitive glucose indicator protein
AU2010326028B2 (en) 2009-12-01 2014-10-02 Exthera Medical Corporation Method for removing cytokines from blood with surface immobilized polysaccharides
SG10201503351RA (en) 2010-01-19 2015-06-29 Harvard College Engineered Opsonin for Pathogen Detection and Treatment
SI2624873T1 (en) 2010-10-06 2020-07-31 President And Fellows Of Harvard College Injectable, pore-forming hydrogels for materials-based cell therapies
WO2013012924A2 (en) * 2011-07-18 2013-01-24 President And Fellows Of Harvard College Engineered microbe-targeting molecules and uses thereof
US9632085B2 (en) * 2012-02-29 2017-04-25 President And Fellows Of Harvard College Rapid antibiotic susceptibility testing
WO2013147610A2 (en) * 2012-03-30 2013-10-03 Jetze Botma Automated selection of microorganisms and identification using maldi
US9937249B2 (en) 2012-04-16 2018-04-10 President And Fellows Of Harvard College Mesoporous silica compositions for modulating immune responses
DE102012011647B4 (en) * 2012-06-08 2020-07-02 Bruker Daltonik Gmbh Analysis of microbes from microcolonies using MALDI mass spectrometry
DK2861273T3 (en) 2012-06-13 2017-11-27 Exthera Medical Corp Use of heparin and carbohydrates for the treatment of cancer.
KR101243631B1 (en) * 2012-07-06 2013-03-15 주식회사 퀀타매트릭스 Microstructure for capturing and releasing microorganism
WO2014144325A1 (en) 2013-03-15 2014-09-18 President And Fellows Of Harvard College Methods and compositions for improving detection and/or capture of a target entity
EP3848044A1 (en) 2013-05-21 2021-07-14 President and Fellows of Harvard College Engineered heme-binding compositions and uses thereof
EP3748010A1 (en) 2013-07-15 2020-12-09 President and Fellows of Harvard College Assays for antimicrobial activity and applications thereof
BR112016002159A2 (en) * 2013-07-30 2017-08-01 Water Lens Llc borate detector composition and analysis solution
US9805171B2 (en) 2013-08-23 2017-10-31 Elwha Llc Modifying a cosmetic product based on a microbe profile
US9557331B2 (en) 2013-08-23 2017-01-31 Elwha Llc Systems, methods, and devices for assessing microbiota of skin
US9811641B2 (en) 2013-08-23 2017-11-07 Elwha Llc Modifying a cosmetic product based on a microbe profile
US20150057574A1 (en) * 2013-08-23 2015-02-26 Elwha Llc Selecting and Delivering Treatment Agents based on a Microbe Profile
US10152529B2 (en) 2013-08-23 2018-12-11 Elwha Llc Systems and methods for generating a treatment map
US10010704B2 (en) 2013-08-23 2018-07-03 Elwha Llc Systems, methods, and devices for delivering treatment to a skin surface
US9470610B2 (en) * 2013-10-22 2016-10-18 The United States Of America As Represented By The Secretary Of The Air Force Methods for using rose bengal for detection of oxidative decomposition of contaminants
EP3065796B1 (en) * 2013-11-08 2020-04-15 ExThera Medical Corporation Methods for diagnosing infectious diseases using adsorption media
EP3083658B1 (en) 2013-12-18 2019-05-08 President and Fellows of Harvard College Crp capture/detection of gram positive bacteria
DE102014206444A1 (en) * 2014-04-03 2015-10-08 Siemens Aktiengesellschaft A method for molecular diagnostics for enriching a nucleic acid from a biological sample
WO2015164198A1 (en) 2014-04-24 2015-10-29 Exthera Medical Corporation Method for removing bacteria from blood using high flow rate
CN107073090A (en) 2014-04-30 2017-08-18 哈佛学院董事会 With reference to vaccine device and kill cancer cell method
WO2016077067A2 (en) 2014-10-27 2016-05-19 President And Fellows Of Harvard College Magnetic capture of a target from a fluid
CA3012602A1 (en) 2015-01-30 2016-08-04 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
WO2016129656A1 (en) * 2015-02-12 2016-08-18 国立大学法人岩手大学 Agent for improving exogenous gene transfer efficiency to mammalian cells
US20180058987A1 (en) * 2015-03-23 2018-03-01 New York University Systems and methods for selecting cellular strains
CN114099793A (en) 2015-04-10 2022-03-01 哈佛学院院长等 Immune cell capture device and methods of making and using same
WO2017024044A1 (en) * 2015-08-03 2017-02-09 President And Fellows Of Harvard College Enhanced electrochemical detection using nanoparticles and precipitation
US10435457B2 (en) 2015-08-06 2019-10-08 President And Fellows Of Harvard College Microbe-binding molecules and uses thereof
JP6947728B2 (en) 2015-09-14 2021-10-13 メディシーブ リミテッド Magnetic filtration equipment and methods
EP3374391B1 (en) 2015-11-10 2024-04-17 Visterra, Inc. Antibody molecule-drug conjugates that specifically binds to lipopolysaccharide and uses thereof
US9834808B2 (en) * 2016-01-21 2017-12-05 SeLux Diagnostics, Inc. Methods for rapid antibiotic susceptibility testing
AU2017210215B2 (en) * 2016-01-21 2022-09-08 SeLux Diagnostics, Inc. Methods for rapid antimicrobial susceptibility testing
US11752238B2 (en) 2016-02-06 2023-09-12 President And Fellows Of Harvard College Recapitulating the hematopoietic niche to reconstitute immunity
MA44252A (en) * 2016-02-16 2018-12-26 Harvard College VACCINES AGAINST PATHOGENIC AGENTS AND THEIR PRODUCTION AND USE PROCESSES
US11911551B2 (en) 2016-03-02 2024-02-27 Exthera Medical Corporation Method for treating drug intoxication
US20170328912A1 (en) * 2016-05-10 2017-11-16 Regents Of The University Of Minnesota Glycopolymer capture matrix for use with surface-enhanced raman spectroscopy detection and related systems and methods
CA3024490A1 (en) 2016-05-16 2017-11-23 President And Fellows Of Harvard College Aqueous biomolecule coupling on co2-plasma-activated surfaces
CN105866408B (en) * 2016-05-17 2017-11-21 北京美康基因科学股份有限公司 A kind of four kinds of enterovirus joint-detection immune chromatography reagent kits and preparation method thereof
CN105866434B (en) * 2016-05-17 2018-04-17 北京美康基因科学股份有限公司 A kind of nine respiratory tract infection pathogen IgM antibody detection immune chromatography reagent kits and preparation method thereof
US10395357B2 (en) * 2016-05-27 2019-08-27 Biomerieux, Inc. Method and apparatus for detection of foam in specimen containers
WO2017209990A1 (en) 2016-05-31 2017-12-07 Exxonmobil Upstream Research Company METHODS FOR lSOLATING NUCLEIC ACIDS FROM SAMPLES
WO2018005514A1 (en) 2016-07-01 2018-01-04 Exxonmobil Upstream Research Company Methods to determine conditions of a hydrocarbon reservoir
CN106199001B (en) * 2016-07-08 2018-04-20 西南大学 The chemiluminescence detection kit and its application method of Streptococcus mutans
US10852311B2 (en) * 2016-07-12 2020-12-01 EMULATE, Inc. Additive channels
US11555177B2 (en) 2016-07-13 2023-01-17 President And Fellows Of Harvard College Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
BR112019000748A2 (en) 2016-07-28 2019-04-24 Medisieve Ltd magnetic method and mixer
KR20190112003A (en) 2017-01-18 2019-10-02 비스테라, 인크. Antibody Molecular-Drug Conjugates and Uses thereof
CN110320364B (en) * 2018-03-30 2023-03-31 洛阳普泰生物技术有限公司 Double-antibody sandwich colloidal gold detection kit, and preparation method and application thereof
US11649478B2 (en) 2018-05-21 2023-05-16 ExxonMobil Technology and Engineering Company Identification of hot environments using biomarkers from cold-shock proteins of thermophilic and hyperthermophilic microorganisms
KR102084688B1 (en) * 2018-06-18 2020-03-04 울산과학기술원 Method for detecting microorganisms using multiple probe hybridization
WO2020037160A2 (en) * 2018-08-15 2020-02-20 Board Of Trustees Of The University Of Alabama, For And On Behalf Of The University Of Alabama In Huntsville Rapid diagnostics of mycobacteria with lectin conjugated particles
CN112840014A (en) 2018-08-22 2021-05-25 生物梅里埃有限公司 Automated compartment position selection detection instrument for newly introduced sample containers and related methods
US10927397B2 (en) 2018-10-16 2021-02-23 Sterilex, Llc Compositions, devices and methods for detecting biofilms
WO2020178420A1 (en) 2019-03-06 2020-09-10 Gambro Lundia Ab Blood treatment device comprising alkaline phosphatase
CN110294810B (en) * 2019-06-26 2021-05-04 中国疾病预防控制中心传染病预防控制所 Recombinant protein containing human IgG1Fc and mannan-binding lectin C-terminal
CN114641580A (en) * 2019-07-23 2022-06-17 斯奈普Dna System and method for detecting and monitoring pathogens
CN110882234B (en) * 2019-11-28 2023-09-12 南京林业大学 Preparation and product of redox responsive cellulose self-assembled drug-loaded microsphere
US20230054472A1 (en) 2019-12-23 2023-02-23 Miraki Innovation Think Tank Llc Sample preparation and microbial analysis
US20230270927A1 (en) 2019-12-23 2023-08-31 Miraki Innovation Think Tank Llc Compositions, devices and methods for diagnosing and treating infectious disease
WO2021202440A1 (en) * 2020-03-30 2021-10-07 Biovector, Inc. Aptamers against sars-cov-2, compositions comprising aptamers against sars-cov-2 and methods of using the same
EP4126064A1 (en) 2020-04-03 2023-02-08 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
CN111440235B (en) * 2020-04-16 2022-11-25 成都中医药大学 Probe for capturing hirudin polypeptide and application thereof
US20210325380A1 (en) * 2020-04-20 2021-10-21 EnLiSense, LLC Disease diagnostics using a multi-configurable sensing array
WO2021252735A1 (en) * 2020-06-11 2021-12-16 Chan Zuckerberg Biohub, Inc. Methods and compositions related to lanthanide-encoded microbeads
US20240011980A1 (en) 2020-06-12 2024-01-11 Miraki Innovation Think Tank Llc Lateral flow assay for rapid detection of pathogens in samples
US20240001019A1 (en) 2020-07-31 2024-01-04 Miraki Innovation Think Tank Llc Mbl-coated substrates having anti-thrombogenic properties
WO2022039716A1 (en) * 2020-08-17 2022-02-24 Hewlett-Packard Development Company, L.P. Microfluidic magnetic microbead interaction
WO2022046558A1 (en) 2020-08-28 2022-03-03 Miraki Innovation Think Tank Llc Therapeutic compositions comprising microbe-targeting molecules and their use in methods of preventing and treating infectious disease
US20240019435A1 (en) 2020-09-25 2024-01-18 Miraki Innovation Think Tank Llc Compositions, devices and methods comprising microbe-targeting molecules for diagnosing and treating infectious disease
US20230416319A1 (en) * 2020-10-01 2023-12-28 Miraki Innovation Think Tank Llc Compositions, devices and methods for identifying, treating and preventing infectious disease using microbe-targeting molecules
WO2022093935A1 (en) 2020-10-27 2022-05-05 Miraki Innovation Think Tank Llc Compositions, systems and methods for pathogen monitoring using microbe-targeting molecules
US20240002325A1 (en) * 2020-10-30 2024-01-04 The Trustees Of Indiana University Oxylipins, processes for making the same, and methods for using the same
GB202019024D0 (en) * 2020-12-02 2021-01-13 Paraytec Ltd Diagnostic testing
US11898146B2 (en) 2020-12-03 2024-02-13 Liv Process, Inc. Aptamers against Clostridium difficile, compositions comprising aptamers against Clostridium difficile and methods of using the same
WO2022125632A1 (en) 2020-12-08 2022-06-16 Miraki Innovation Think Tank Llc Chimeric antigen receptor-expressing cells targeting microbe-associated molecular patterns
WO2022151333A1 (en) * 2021-01-15 2022-07-21 传鸣(宁波)化学科技有限公司 Mixture for enriching microorganisms, and method and application
CN112877274B (en) * 2021-01-29 2024-02-09 南京大学 Extracellular vesicle magnetic imprinting material and preparation method and application thereof
CN113155942A (en) * 2021-04-02 2021-07-23 传鸣(宁波)化学科技有限公司 Application of magnetic functionalized magnetic nano material and mixed microorganism identification method
US20220364973A1 (en) * 2021-05-13 2022-11-17 Honeywell International Inc. In situ fluid sampling device and method of using the same
US20230110757A1 (en) * 2021-10-13 2023-04-13 Evoq Nano, Inc. Methods for treating animals, feed, drinking water, wash water, processing equipment, packaging materials, and food products
CN116448996B (en) * 2023-03-22 2023-11-21 卡秋(江苏)生物科技有限公司 Preparation method of polymerase-antibody complex with bead structure
CN117018210B (en) * 2023-04-23 2024-05-07 国科温州研究院(温州生物材料与工程研究所) Swimming cell robot and preparation method thereof
CN116850977A (en) * 2023-07-28 2023-10-10 广州康盛生物科技股份有限公司 Directional coupling immunoadsorbent as well as preparation method and application thereof

Family Cites Families (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
NL154598B (en) 1970-11-10 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3832253A (en) 1973-03-21 1974-08-27 Baxter Laboratories Inc Method of making an inflatable balloon catheter
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
JPS5418198A (en) 1977-07-09 1979-02-09 Toshimitsu Niwa Artificial intraretinal device
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4425330A (en) 1981-05-20 1984-01-10 Cornell Research Foundation, Inc. Bovine mastitis vaccine and method for detecting efficacy thereof
US4667014A (en) 1983-03-07 1987-05-19 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
JPS60500548A (en) * 1982-12-03 1985-04-18 イ−・アイ・デユポン・ド・ネモア−ス・アンド・コンパニ− Chromogenic support immunoassay
WO1984002193A1 (en) 1982-12-03 1984-06-07 Du Pont Chromogenic support immunoassay
CA1200416A (en) 1983-05-13 1986-02-11 Societe Des Produits Nestle S.A. Food process
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
JPH0718875B2 (en) 1987-06-19 1995-03-06 ヤマサ醤油株式会社 Method for measuring trace substance content in blood or body fluids
ATE165980T1 (en) 1987-08-20 1998-05-15 Childrens Medical Center NUCLIC ACID FRAGMENTS ENCODING MANNOSE BINDING FRAGMENTS FROM HUMAN MANNOSE BINDING PROTEIN
US5270199A (en) 1987-08-20 1993-12-14 The Children's Medical Center Corporation Human mannose-binding protein
US5093268A (en) 1988-04-28 1992-03-03 Igen, Inc. Apparatus for conducting a plurality of simultaneous measurements of electrochemiluminescent phenomena
MY105227A (en) 1989-01-25 1994-08-30 Commonwealth Scient & Industrial Research Organization Polypeptides, antigens or vaccines protective against babesiosis.
US5137810A (en) 1989-04-26 1992-08-11 The University Of North Carolina Method of determining the gram sign of bacteria
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5252701A (en) 1990-07-06 1993-10-12 American Cyanamid Company Segmented absorbable copolymer
DE69131576T2 (en) 1990-07-30 2000-03-16 Novartis Ag INSECTICIDE PROTEINS
US5135875A (en) 1990-08-15 1992-08-04 Abbott Laboratories Protein precipitation reagent
CA2048302A1 (en) 1990-08-15 1992-02-16 Victoria P. Meucci Solubilization reagent for biological test samples
GB9020075D0 (en) 1990-09-14 1990-10-24 Filler Aaron G Contrast agents for magnetic resonance imaging of axonal transport
JPH04130274A (en) * 1990-09-20 1992-05-01 Kyoto Ikagaku Kenkyusho:Kk Method for analyzing and detecting sugar protein
JPH04167172A (en) 1990-10-31 1992-06-15 Nec Corp Vector processor
US5783179A (en) 1991-08-09 1998-07-21 Syntex (U.S.A.) Inc. C-reactive protein fragment with immunomodulatory activity
DE69230643T2 (en) 1991-11-27 2000-06-21 Immtech Int Inc METHOD FOR TREATING VIRAL INFECTIONS
US5405832A (en) 1991-11-27 1995-04-11 Immtech International Inc. Method of treating non-streptococcal bacterial infections
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5874238A (en) 1993-02-26 1999-02-23 Immtech International Inc. Mutant protein and methods and materials for making and using it
US5283238A (en) 1992-04-24 1994-02-01 Immtech International, Inc. Methods of treating cancer using modified C-reactive protein
US6703219B1 (en) 1993-02-26 2004-03-09 Immtech International Inc. Mutant protein and methods and materials for making and using it
US5565215A (en) 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
IT1271486B (en) 1993-10-12 1997-05-28 Italfarmaco Spa IMMUNOMODULATORY OLIGOPEPTIDES DERIVED FROM FRAGMENTS OF C-REACTIVE PROTEIN
US6066448A (en) 1995-03-10 2000-05-23 Meso Sclae Technologies, Llc. Multi-array, multi-specific electrochemiluminescence testing
AUPN214095A0 (en) 1995-04-03 1995-04-27 Australian Water Technologies Pty Ltd Method for detecting microorganisms using flow cytometry
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
BR9708387A (en) 1996-03-28 2000-01-04 Genitrix Llc Process for vaccination of a mammal to a selected antigen, host and pathogenic cells, vaccine composition, nucleic acid, and engineered opsonin.
ZA973051B (en) 1996-04-24 1998-10-12 Genentech Inc Type c lectins
US6117977A (en) 1996-04-24 2000-09-12 Genentech, Inc. Type C lectins
FR2751229B1 (en) 1996-07-19 1998-11-27 Rhone Merieux POLYNUCLEOTIDE VACCINE FORMULA IN PARTICULAR AGAINST RESPIRATORY PATHOLOGY OF CATTLE
US5980948A (en) 1996-08-16 1999-11-09 Osteotech, Inc. Polyetherester copolymers as drug delivery matrices
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
CN1256700A (en) 1997-04-03 2000-06-14 吉尔福德药物有限公司 Biodegradable terephthalate polyester-poly(phosphate) polymers, compositions, articles,and method for making and using the same
WO1998047912A1 (en) 1997-04-22 1998-10-29 Life Technologies, Inc. Methods for the production of aslv reverse transcriptases composed of multiple subunits
IL121191A0 (en) 1997-06-29 1997-11-20 Yeda Res & Dev Synthetic peptides and pharmaceutical compositions comprising them
US6045925A (en) 1997-08-05 2000-04-04 Kansas State University Research Foundation Encapsulated nanometer magnetic particles
JPH11206378A (en) 1998-01-23 1999-08-03 Fuso Pharmaceutical Industries Ltd Recombinant human mannan binding protein and its production
US7049099B2 (en) 1998-01-23 2006-05-23 Fuso Pharmaceutical Industries, Ltd. Recombinant human mannan-binding proteins and producing method of the same
US6528624B1 (en) * 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
KR100309918B1 (en) 1998-05-16 2001-12-17 윤종용 Liquid crystal display having wide viewing angle and method for manufacturing the same
US6429192B1 (en) 1998-06-10 2002-08-06 Statens Serum Institut Purification process for production of mannan-binding lectin and an MBL medicinal product
DE69921329T2 (en) 1998-07-31 2006-02-09 Asahi Kasei Kabushiki Kaisha ANTI-L7 / L12 ANTIBODIES FOR THE DETECTION OF BACTERIA
US6153212A (en) 1998-10-02 2000-11-28 Guilford Pharmaceuticals Inc. Biodegradable terephthalate polyester-poly (phosphonate) compositions, articles, and methods of using the same
US6419709B1 (en) 1998-10-02 2002-07-16 Guilford Pharmaceuticals, Inc. Biodegradable terephthalate polyester-poly(Phosphite) compositions, articles, and methods of using the same
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6388047B1 (en) 1999-04-12 2002-05-14 Cornell Research Foundation, Inc. Hydrogel-forming system with hydrophobic and hydrophilic components
JP2002544286A (en) 1999-05-14 2002-12-24 ティール，ステフェン Novel application of mannan-binding lectin (MBL) in the treatment of individuals with poor immune response
AU782496B2 (en) 1999-07-13 2005-08-04 Bolder Biotechnology, Inc. Immunoglobulin fusion proteins
US6503761B1 (en) 1999-10-19 2003-01-07 Kimberly-Clark Worldwide, Inc. Selective removal of contaminants from a surface using articles having magnets
US6471968B1 (en) 2000-05-12 2002-10-29 Regents Of The University Of Michigan Multifunctional nanodevice platform
US6503538B1 (en) 2000-08-30 2003-01-07 Cornell Research Foundation, Inc. Elastomeric functional biodegradable copolyester amides and copolyester urethanes
JP2002165591A (en) * 2000-09-25 2002-06-11 Jsr Corp Magnetic particle and method for using the same
WO2002032292A2 (en) 2000-10-18 2002-04-25 The Board Of Trustess Of The Leland Stanford Junior University Methods for development and use of diagnostic and therapeutic agents
US6958216B2 (en) 2001-01-10 2005-10-25 The Trustees Of Boston College DNA-bridged carbon nanotube arrays
WO2002081729A2 (en) 2001-04-06 2002-10-17 California Institute Of Technology Nucleic acid amplification utilizing microfluidic devices
JP4335002B2 (en) 2001-08-02 2009-09-30 コーネル・リサーチ・ファンデーション・インコーポレイテッド Biodegradable polyhydric alcohol ester
GB0119274D0 (en) 2001-08-08 2001-10-03 Univ Durham Fusion proteins for insect control
US6900292B2 (en) 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
JP4355210B2 (en) 2001-11-30 2009-10-28 フルイディグム コーポレイション Microfluidic device and method of using microfluidic device
AU2002359815A1 (en) 2001-12-19 2003-07-09 Immunex Corporation C-type lectin polypeptide, polynucleotide and methods of making and use thereof
US6676729B2 (en) 2002-01-02 2004-01-13 International Business Machines Corporation Metal salt reduction to form alloy nanoparticles
US6844426B2 (en) 2002-02-06 2005-01-18 Toyo Boseki Kabushiki Kaisha Magnetic carrier capable of binding with protein and purification method of protein utilizing the magnetic carrier
US7125839B2 (en) 2002-02-07 2006-10-24 Massachusetts Institute Of Technology Anti-pathogen treatments
EP1339075A1 (en) 2002-02-25 2003-08-27 Motorola, Inc. Magnetic nanomaterials and synthesis method
US6878445B2 (en) 2002-03-08 2005-04-12 Fuji Photo Film Co., Ltd. Nanoparticle coated material and production method of same
EP1344533B1 (en) 2002-03-15 2006-08-23 Natimmune A/S Pharmaceutical compositions comprising mannose binding lectin
US20030180814A1 (en) 2002-03-21 2003-09-25 Alastair Hodges Direct immunosensor assay
US7211396B2 (en) 2002-04-18 2007-05-01 Antibodyshop A/S Antibody pairs and kits for immunochemical determination of mannan-binding lectin
CA2483441A1 (en) 2002-04-24 2003-11-06 The Council Of The Queensland Institute Of Medical Research Mannose binding lectin and uses thereof
US20040018611A1 (en) 2002-07-23 2004-01-29 Ward Michael Dennis Microfluidic devices for high gradient magnetic separation
EP1573047B1 (en) 2002-08-20 2013-11-13 OpSaniTx LLC Lectin compositions and methods for modulating an immune response to an antigen
US7629440B2 (en) 2002-08-20 2009-12-08 Genitrix, Llc Lectin compositions and methods for modulating an immune response to an antigen
WO2004024925A2 (en) 2002-09-10 2004-03-25 Natimmune A/S Collectin-complement activating protein chimeras
GB2393728A (en) 2002-10-04 2004-04-07 Nanomagnetics Ltd Magnetic nanoparticles
US7030989B2 (en) 2002-10-28 2006-04-18 University Of Washington Wavelength tunable surface plasmon resonance sensor
EP1417965A1 (en) 2002-11-07 2004-05-12 Vereniging Voor Christelijk Wetenschappelijk Onderwijs C-type lectin binding molecules, identification and uses thereof
WO2004084802A2 (en) * 2002-11-21 2004-10-07 Polytechnic University Glycoconjugate sensors
CN101124315A (en) 2003-01-17 2008-02-13 伊势龙医学股份有限公司 Method for removal of viruses from blood by lectin affinity hemodialysis
DE10331439B3 (en) 2003-07-10 2005-02-03 Micromod Partikeltechnologie Gmbh Magnetic nanoparticles with improved magnetic properties
US20050014932A1 (en) 2003-05-15 2005-01-20 Iogenetics, Llc Targeted biocides
DE10325752A1 (en) 2003-06-06 2004-12-30 Faustus Forschungs Cie. Translational Cancer Research Gmbh Lectin conjugates
GB0313259D0 (en) 2003-06-09 2003-07-16 Consejo Superior Investigacion Magnetic nanoparticles
US7396589B2 (en) 2003-07-31 2008-07-08 Industrial Technology Research Institute Core-shell magnetic nanoparticles comprising an inner-transition element
TW593158B (en) 2003-07-31 2004-06-21 Ind Tech Res Inst Magnetic nanoparticle
EP1678197A4 (en) 2003-10-24 2008-05-07 Ludwig Inst Cancer Res Methods and compositions for pdgf-c activation and inhibition
US7781226B2 (en) 2004-02-27 2010-08-24 The Board Of Regents Of The University Of Texas System Particle on membrane assay system
AU2005227326B2 (en) 2004-03-24 2009-12-03 Xencor, Inc. Immunoglobulin variants outside the Fc region
CA2464227C (en) 2004-03-31 2009-02-03 Jean-Louis Major Double action piston assembly
SE0401033D0 (en) 2004-04-20 2004-04-20 Amersham Biosciences Ab Device and method for protein analysis
WO2006073432A2 (en) 2004-04-30 2006-07-13 The General Hospital Corporation Mannose-binding lectin knock-out mice and methods of use thereof
WO2007001332A2 (en) 2004-08-04 2007-01-04 University Of Massachusetts Anti-pathogen immunoadhesins
WO2006018428A2 (en) 2004-08-20 2006-02-23 Novo Nordisk A/S Hemopexin fusion proteins
US20110098184A1 (en) 2004-10-15 2011-04-28 Day Anthony G Competitve differntial screeing
ES2360504T3 (en) 2004-10-28 2011-06-06 Dobeel Co., Ltd. METHOD FOR MASSED MULTIMERIC LECTIN MASS PRODUCTION.
US20060141547A1 (en) 2004-11-16 2006-06-29 Das Hasi R Novel diagnostic marker, a diagnostic kit and a method for diagnosis of rheumatoid arthritis
US7172906B2 (en) 2004-11-16 2007-02-06 Dade Behring Inc. Reduction of non-specific binding in assays
US8084275B2 (en) 2005-02-08 2011-12-27 Fujifilm Corporation Magnetic composite body, production method thereof, method for removing substance with mannose on its surface, and method for concentrating substance with mannose on its surface
US7462446B2 (en) 2005-03-18 2008-12-09 University Of Washington Magnetic nanoparticle compositions and methods
US7700193B2 (en) 2005-04-08 2010-04-20 Industrial Technology Research Institute Core-shell structure with magnetic, thermal, and optical characteristics and manufacturing method thereof
JP2008535872A (en) * 2005-04-11 2008-09-04 ナットイムネ・アクティーゼルスカブ Novel cancer application of mannan-binding lectin (MBL) in the treatment of individuals with immune disorders
US20070031819A1 (en) 2005-04-26 2007-02-08 University Of Washington Microfluidic systems for biological and molecular analysis and methods thereof
WO2006119968A2 (en) 2005-05-09 2006-11-16 Biosphere Medical S.A. Compositions and methods using microspheres and non-ionic contrast agents
US20070231833A1 (en) 2005-05-23 2007-10-04 Arcidiacono Steven M Labeled antimicrobial peptides and method of using the same to detect microorganisms of interest
US20070072247A1 (en) 2005-08-31 2007-03-29 Academia Sinica Methods and reagents for the analysis and purification of polysaccharides
US20070264199A1 (en) 2005-09-26 2007-11-15 Labhasetwar Vinod D Magnetic nanoparticle composition and methods for using the same
CN101273258A (en) 2005-09-30 2008-09-24 卡钳生命科学股份有限公司 Microfluidic device for purifying a biological component using magnetic beads
WO2007044642A2 (en) 2005-10-06 2007-04-19 President And Fellows Of Harvard College And Children's Medical Center Corporation Device and method for combined microfluidic-micromagnetic separation of material in continuous flow
WO2007050661A2 (en) 2005-10-26 2007-05-03 Science & Technology Corporation @ Unm C-reactive protein and its use to treat systemic lupus erythematosus and related conditions
US20070269818A1 (en) 2005-12-28 2007-11-22 Affymetrix, Inc. Carbohydrate arrays
US20090181041A1 (en) 2006-01-23 2009-07-16 Jan Holgersson Production of proteins carrying oligomannose or human-like glycans in yeast and methods of use thereof
KR20080096567A (en) 2006-02-03 2008-10-30 마이크로칩 바이오테크놀로지스, 인크. Microfluidic devices
WO2007111938A2 (en) 2006-03-23 2007-10-04 The General Hospital Corporation Inflammation-inhibitory serum factors and uses thereof
WO2007111496A1 (en) 2006-03-28 2007-10-04 Universiteit Utrecht Holding B.V. Improved carbohydrate recognition domains
US8454934B2 (en) 2006-05-25 2013-06-04 Canadian Blood Services High molecular weight chelation structure
EP1862541A1 (en) 2006-06-01 2007-12-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Polypeptides derived from the hemopexin-like domain of metalloproteinase MMP-2
US7883855B2 (en) 2006-07-21 2011-02-08 Abbott Laboratories Immunosuppressant drug extraction reagent for immunoassays
US8273310B2 (en) 2006-09-05 2012-09-25 Samsung Electronics Co., Ltd. Centrifugal force-based microfluidic device for nucleic acid extraction and microfluidic system including the microfluidic device
KR101343034B1 (en) 2006-09-05 2013-12-18 삼성전자 주식회사 Centrifugal microfluidic device for target protein detection and microfluidic system comprising the same
US8088596B2 (en) 2006-10-10 2012-01-03 Oakland University Method of microorganism detection using carbohydrate and lectin recognition
US8551333B2 (en) 2007-04-05 2013-10-08 The Regents Of The University Of California Particle-based microfluidic device for providing high magnetic field gradients
CA2682605A1 (en) 2007-04-18 2008-10-30 Zymogenetics, Inc. Single chain fc, methods of making and methods of treatment
WO2008130618A1 (en) 2007-04-19 2008-10-30 The Charles Stark Draper Laboratory, Inc. Method and apparatus for separating particles, cells, molecules and particulates
WO2008143954A2 (en) 2007-05-14 2008-11-27 Biogen Idec Ma Inc. Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
JP5577243B2 (en) 2007-05-30 2014-08-20 ポステク アカデミー−インダストリー ファウンデイション Immunoglobulin fusion protein
US20100204155A1 (en) 2007-09-11 2010-08-12 Dorian Bevec Use of the peptide sfllr-oh and muramyl dipeptide as therapeutic agents
WO2009058853A2 (en) 2007-10-29 2009-05-07 Purdue Research Foundation Hybrid microfluidic spr and molecular imaging device
JP2011501958A (en) 2007-10-29 2011-01-20 バージニア テック インテレクチュアル プロパティーズ インコーポレーテッド Porcine DC-SIGN, ICAM-3 and LSECtin and their use
JP2011502520A (en) * 2007-11-09 2011-01-27 アナフォア インコーポレイテッド Mannose-binding lectin fusion protein for disease treatment
ES2326109B1 (en) 2007-12-05 2010-06-25 Consejo Superior De Investigaciones Cientificas SELECTIVE AND NON INVASIVE SEPARATION AND EXTRACTION MICRODISPOSITIVE OF PARTICLES IN POLIDISPERSE SUSPENSIONS, MANUFACTURING PROCEDURE AND ITS APPLICATIONS.
US20100266558A1 (en) 2007-12-18 2010-10-21 Dov Zipori Method and assay for glycosylation pattern detection related to cell state of stem cells
US20110183398A1 (en) 2007-12-31 2011-07-28 3M Innovative Properties Microorganism-capturing compositions and methods
WO2009126346A2 (en) 2008-01-18 2009-10-15 The General Hospital Corporation Methods for prevention and treatment of infections with supraphysiological doses of mannan-binding lectin (mbl) and ficolin-mbl fusion proteins
CN101990575B (en) 2008-03-28 2015-06-17 国立大学法人北海道大学 Anti-(influenza a virus subtype h5 hemagglutinin) monoclonal antibody
CN101983238B (en) 2008-03-31 2013-06-12 日本烟草产业株式会社 Method for concentration of virus
US20110053145A1 (en) 2008-03-31 2011-03-03 Japan Tobacco Inc. Quantitation method of virus
US20100323429A1 (en) 2008-04-10 2010-12-23 Yu-Chen Hu Methods for purifying baculovirus
US8865876B2 (en) 2008-06-02 2014-10-21 California Institute Of Technology Engineered lectin oligomers with antiviral activity
JP2011522044A (en) 2008-06-03 2011-07-28 エスティーシー． ユーエヌエム Development of C-reactive protein mutants with improved therapeutic utility in immune thrombocytopenia and lupus nephritis
JP2010122205A (en) 2008-08-29 2010-06-03 Sysmex Corp Method for detecting measles virus, membrane assay test device, and membrane assay test kit
US20110159000A1 (en) 2008-09-05 2011-06-30 The Regents Of The University Of California Antibodies with mannose binding lectin effector function for inhibiting pathologic inflammatory conditions
WO2010065765A2 (en) 2008-12-04 2010-06-10 Aethlon Medical, Inc. Affinity capture of circulating biomarkers
CN106243229B (en) 2008-12-22 2019-09-06 国立大学法人北海道大学 Protein material and its manufacturing method with triple-helix structure
CN102369291A (en) 2009-01-23 2012-03-07 比奥根艾迪克Ma公司 Stabilized Fc polypeptides with reduced effector function and methods of use
WO2010088261A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Binding-site modified lectins and uses thereof
US20130012451A1 (en) 2009-12-21 2013-01-10 The Research Foundation Of State University Of New York Compositions and methods for inhibiting mmp-9-mediated cell migration
US20130157283A1 (en) 2010-01-19 2013-06-20 President And Fellows Of Harvard College Rapid pathogen diagnostic device and method
SG10201503351RA (en) 2010-01-19 2015-06-29 Harvard College Engineered Opsonin for Pathogen Detection and Treatment
WO2011103144A1 (en) 2010-02-16 2011-08-25 President And Fellows Of Harvard College Methods and systems for detection of microbes
KR101140029B1 (en) 2010-02-23 2012-06-21 한국식품연구원 Preparation method of antigen-immobilized immuno- fluorescence slide and the immuno-fluoroscence slide made by the method
US20130123185A1 (en) 2010-08-06 2013-05-16 Emory University Methods of treating and diagnosing acute chest syndrome
WO2012050874A2 (en) 2010-09-28 2012-04-19 Soares Miguel P Targeting heme for the treatment of immune mediated inflammatory diseases
US9353646B2 (en) 2011-01-19 2016-05-31 President And Fellows Of Harvard College Slippery surfaces with high pressure stability, optical transparency, and self-healing characteristics
WO2012135834A2 (en) 2011-04-01 2012-10-04 President And Fellows Of Harvard College Dialysis like therapeutic (dlt) device
WO2012142515A2 (en) 2011-04-13 2012-10-18 Bristol-Myers Squibb Company Fc fusion proteins comprising novel linkers or arrangements
WO2013012924A2 (en) * 2011-07-18 2013-01-24 President And Fellows Of Harvard College Engineered microbe-targeting molecules and uses thereof

Also Published As

Publication number Publication date
AU2017254907B2 (en) 2019-08-15
EP3081937B1 (en) 2019-11-13
ZA201400560B (en) 2020-05-27
US10526399B2 (en) 2020-01-07
AU2017254907A1 (en) 2017-11-23
JP2014523914A (en) 2014-09-18
US9593160B2 (en) 2017-03-14
JP2020128421A (en) 2020-08-27
US20140227723A1 (en) 2014-08-14
WO2013012924A2 (en) 2013-01-24
CA2842321A1 (en) 2013-01-24
US11795212B2 (en) 2023-10-24
US10865235B2 (en) 2020-12-15
JP2019077687A (en) 2019-05-23
US20170362307A1 (en) 2017-12-21
AU2012284097A1 (en) 2014-02-06
ZA202000056B (en) 2021-06-30
WO2013012924A3 (en) 2013-04-11
JP7270364B2 (en) 2023-05-10
EP3081937A1 (en) 2016-10-19
CA2842321C (en) 2022-05-03
EP2734843A2 (en) 2014-05-28
CA3149018A1 (en) 2013-01-24
US20210155677A1 (en) 2021-05-27
US20200239552A1 (en) 2020-07-30
AU2012284097B2 (en) 2017-08-03
JP7307030B2 (en) 2023-07-11
JP2022034056A (en) 2022-03-02

Similar Documents

Publication Publication Date Title
ZA202000056B (en) Engineered microbe-targeting molecules and uses thereof
IL281148A (en) Novel kif5b-ret fusion molecules and uses thereof
HUS2100012I1 (en) 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors
HK1214831A1 (en) Novel fusion molecules and uses thereof
IL233051A0 (en) Anti-phf-tau-antibodies and their uses
ZA201307302B (en) Cd37-binding molecules and immunoconjugates thereof
IL229844B (en) Anti-psgl-1-antibodies and uses thereof
HK1246326A1 (en) Thrombin-binding antibody molecules and uses thereof
GB201110783D0 (en) Methods and uses
GB201116774D0 (en) Uses and methods
EP2716359A4 (en) Complex and uses thereof
GB201111775D0 (en) Compounds and uses thereof
PT2790739T (en) Nanoparticles and uses thereof
GB201106357D0 (en) Composition and uses thereof
EP2693879A4 (en) Migrastatins and uses thereof
GB201108490D0 (en) Methods and uses
GB201121726D0 (en) Compounds and uses thereof
GB201121551D0 (en) Compounds and uses thereof
LT3689878T (en) 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors